Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Weber, T; Zweiker, R; Watschinger, B; Grüner, P; Koppelstätter, C; Brandt, MC; Horina, J; Brussee, H; Hohenstein, K; Lambert, T; Auer, J; Hoppe, UC.
Clinical application of interventional renal sympathetic denervation: recommendations of the Austrian Society of Hypertension 2012.
Wien Klin Wochenschr. 2012; 124(21-22):789-798
Doi: 10.1007/s00508-012-0257-3
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Brussee Helmut
- Horina Joerg
- Zweiker Robert
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Increased activity of the sympathetic nervous system plays a major role in the pathophysiology of primary arterial hypertension. Interventional renal sympathetic denervation (RSD) is a novel percutaneous treatment, decreasing sympathetic activity and consecutively blood pressure by ablating sympathetic nervous fibers located in the adventitia of the renal arteries. The procedure has been tested in several clinical trials in patients with resistant hypertension (defined as systolic office blood pressure > 160 mmHg-in diabetic patients > 150 mmHg-treated with ³ 3 antihypertensive drugs) and caused a meaningful blood pressure reduction, lasting for at least 3 years. So far, no major adverse events have been identified; however, data on the long-term consequences are lacking. The present position paper of the Austrian Society of Hypertension is aiming to assist in choosing possible indications for RSD in clinical routine, based on the available evidence in 2012.
- Find related publications in this database (using NLM MeSH Indexing)
- -
- Humans -
- Hypertension, Renal - surgery
- Kidney - innervation
- Practice Guidelines as Topic -
- Sympathectomy - methods
- Find related publications in this database (Keywords)
- Renal sympathetic denervation
- Resistant hypertension
- Interventional treatment